Authorized purpose: Transthoracic echocardiography view classification, cardiac structure segmentation, functional measurements and Doppler review and report support.
Clinical role
Measurement and review aid for a trained clinician; it does not replace professional interpretation of the echocardiogram.
Images and patients
Ultrasound · Heart/Cardiovascular
Key limitation
Keep in mind: The FDA validation used a separate 200-patient test set and an expert reference standard; subgroup analyses included age, sex, ethnicity, pathology, ultrasound vendor/model/year and image quality. The exact packet does not establish a universal result for other populations or configurations.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Transthoracic echocardiography view classification, cardiac structure segmentation, functional measurements and Doppler review and report support.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Heart/Cardiovascular Input: Transthoracic echocardiography images and Doppler data from the supported examination workflow.
Who uses it?Intended users: Healthcare professionals interpreting transthoracic echocardiography studies.
What does the software produce?Output: Automated view classification, cardiac structure segmentation, Doppler and functional measurements, and more than 100 measurement outputs for clinician review.
What is its most important limitation?Key limitation: The FDA validation used a separate 200-patient test set and an expert reference standard; subgroup analyses included age, sex, ethnicity, pathology, ultrasound vendor/model/year and image quality. The exact packet does not establish a universal result for other populations or configurations.
Clinical takeaway. Clinical role: Transthoracic echocardiography view classification, cardiac structure segmentation, functional measurements and Doppler review and report support.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA validation used 200 echocardiography cases from 200 patients with three human experts as reference. The endpoint was the difference between AI-versus-expert mean absolute error and inter-expert mean absolute error, expressed as a percentage of human-expert MAE; the upper 95% confidence bound had to be below +25% relative to that denominator. The manufacturer reports a relative upper confidence bound below zero without quantifying its magnitude in the reviewed summary.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Transthoracic echocardiography view classification, cardiac structure segmentation, functional measurements and Doppler review and report support.
Automated view classification, cardiac structure segmentation, Doppler and functional measurements, and more than 100 measurement outputs for clinician review.
The FDA validation used a separate 200-patient test set and an expert reference standard; subgroup analyses included age, sex, ethnicity, pathology, ultrasound vendor/model/year and image quality. The exact packet does not establish a universal result for other populations or configurations.
The exact FDA validation used 200 echocardiography cases from 200 patients with three human experts as reference. The endpoint was the difference between AI-versus-expert mean absolute error and inter-expert mean absolute error, expressed as a percentage of human-expert MAE; the upper 95% confidence bound had to be below +25% relative to that denominator. The manufacturer reports a relative upper confidence bound below zero without quantifying its magnitude in the reviewed summary.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA validation used 200 echocardiography cases from 200 patients with three human experts as reference. The endpoint was the difference between AI-versus-expert mean absolute error and inter-expert mean absolute error, expressed as a percentage of human-expert MAE; the upper 95% confidence bound had to be below +25% relative to that denominator. The manufacturer reports a relative upper confidence bound below zero without quantifying its magnitude in the reviewed summary.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
EchoConfidence measurement validation
DesignRetrospective clinical validation against three human expert readers
Population200 transthoracic echocardiography cases from 200 patients with subgrouping by demographics, pathology, vendor, model, year and image quality
Scopeexact submission
Tested versionEchoConfidence release reviewed in K250670
Samplen=200
IndependenceSponsor or vendor study
K250670 FDA 510(k) summary
The FDA summary says the test data were separate from training data and states the acceptance criterion; it does not establish an observed aggregate performance value in the reviewed text.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Transthoracic echocardiography images and Doppler data from the supported examination workflow.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The current EchoConfidence family page describes vendor-neutral PACS and EHR integration and a human-in-the-loop review, refine and approve workflow; it does not establish the exact K250670 deployment configuration.
Scope: Product family.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-10-27 ·
Returned objects
Source context, not route validation: Automated view classification, cardiac structure segmentation, Doppler and functional measurements, and more than 100 measurement outputs for clinician review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Automated view classification, cardiac structure segmentation, Doppler and functional measurements, and more than 100 measurement outputs for clinician review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The current EchoConfidence family page describes vendor-neutral PACS and EHR integration and a human-in-the-loop review, refine and approve workflow; it does not establish the exact K250670 deployment configuration.
MyCardium AI Ltd announced it was awarded ISO 27001 certification by BSI (posted 2024-01-12) for its information security management, alongside ISO 13485 compliant development processes.
Vendor-wide
Checked 2026-10-27
Vendor statement; certificate not read. Company-level statement applied to the Mycardium AI Limited entry. Exact-release scope is not established.
The FDA labeling describes automated view classification, segmentation and more than 100 measurements across chambers, valves, vessels and pericardium.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-07Last searched
22Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The stored candidate metadata contained empty PubMed and clinical-trial ID arrays; metadata was screened, not full-text or registry-reviewed. The stored recall candidate record was empty and no event was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor manual, peer reviewed publication, clinical trial registry, recall database, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission
No numeric price was published in the reviewed sources.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Mycardium AI reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.
Deployment: Not verified - checked 2026-10-27 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Ligence Heart is a fully automated software platform that processes, analyses and makes measurements on acquired transthoracic cardiac ultrasound images, automatically producing a full report with measurements of several key cardiac structural and functional parameters. The data produced by this software is intended to be used to support qualified cardiologists or sonographers for clinical decision making. Ligence Heart is indicated for use in adult patients. Ligence Heart has not been validated for the assessment of congenital heart disease, valve disease, pericardial disease, and/or intra-cardiac lesions (e.g., tumors, thrombi). Limitations: Poor image capture will lead to poor annotations and subsequent measurements. Multiple image quality algorithms are used to filter out images of poor quality. Our software complements good patient care and does not exempt the user from the responsibility to provide supervision, clinically review the patient, and make appropriate clinical decisions. If no gender is present, female referenced guideline values will be used for conclusions. If Body Surface Area (BSA) is not present, indexed values cannot be provided. During image acquisition, inappropriate use of the echo machine, use of non-cardiac ultrasound probes, or use of suboptimal settings (e.g., gain, contrast, depth) may lead to lower accuracy of the software. Ligence Heart has not been validated in patients with prosthetic or surgically altered cardiac valves, implantable intracardiac devices, or irregular (non-sinus) rhythm; these conditions may affect automated measurement accuracy.
Authorized purpose: PVAD IQ supports qualified-physician clinical decision support by identifying the aortic annulus and PVAD inlet, calculating their mean distance, and identifying clips acceptable for this measurement.
Authorized purpose: Automated echocardiographic LV and RV function, wall-motion and strain, bladder-volume and image-quality measurements for clinician review.
Authorized purpose: Measures global longitudinal strain from apical four-chamber cardiac ultrasound images in adult patients with suspected disease as an aid to diagnostic analysis; users can accept or reject measurements.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.